文献速递临床试验与 GCP基础与转化研究

磁共振成像对比常规达标治疗策略对类风湿关节炎疾病活动度缓解与影像学进展的影响:IMAGINE-RA随机临床试验

Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项在丹麦9家医院开展的2年随机多中心试验纳入200例临床缓解的类风湿关节炎患者,比较MRI引导与常规临床达标治疗策略。结果显示两组在24个月时的DAS28-CRP缓解率和无影像学进展比例均无显著差异,MRI引导组严重不良事件更多。

要点

  • MRI引导达标治疗未改善临床缓解率
  • MRI引导未减少影像学进展
  • MRI组严重不良事件更多(17% vs 6%)

核心结论

  • 在临床缓解的RA患者中,MRI引导达标治疗策略相比常规达标治疗未改善疾病活动度缓解率或减少影像学进展。
  • 这些发现不支持使用MRI引导策略治疗RA患者。

研究设计与样本

  • 2年随机多中心试验,在丹麦9家医院开展。
  • 纳入200例临床缓解(DAS28-CRP<3.2且无肿胀关节)的RA患者,2012年4月至2015年6月入组,末次随访2017年4月。
  • 按1:1随机分配至MRI引导达标治疗组或常规达标治疗组。

主要发现

  • MRI引导组76例(76%)和常规组95例(95%)完成研究。
  • 10个关键次要终点中8个为阴性,2个显示MRI达标治疗组有统计学显著获益。
  • MRI引导组17例(17%)和常规组6例(6%)发生严重不良事件。

关键数值与推荐

  • MRI引导组治疗目标为无MRI骨髓水肿联合临床缓解(DAS28-CRP≤3.2且无肿胀关节)。
  • 常规组治疗目标为临床缓解。

临床怎么用

  • 对于已达临床缓解的RA患者,不应常规采用MRI引导的达标治疗策略。
  • MRI引导策略未显示临床或影像学优势,且严重不良事件更多。

局限性

  • 研究仅纳入丹麦9家医院的患者,外推性需谨慎。
  • 完成研究比例在两组间存在差异(MRI组76% vs 常规组95%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether using magnetic resonance imaging (MRI) to guide treatment in patients with rheumatoid arthritis (RA) improves disease activity and slows joint damage progression is unknown. OBJECTIVE: To determine whether an MRI-guided treat-to-target strategy vs a conventional clinical treat-to-target strategy improves outcomes in patients with RA in clinical remission. DESIGN, SETTING, AND PARTICIPANTS: Two-year, randomized, multicenter trial conducted at 9 hospitals in Denmark. Two hundred patients with RA in clinical remission (disease activity score in 28 joints-C-reactive protein [DAS28-CRP] <3.2 and no swollen joints) were enrolled between April 2012 and June 2015. The final follow-up visit was April 2017. INTERVENTIONS: Patients were randomly allocated (1:1) to an MRI-guided vs a conventional treat-to-target strategy. In the MRI-guided group, the treatment goal was absence of MRI bone marrow edema combined with clinical remission, defined as DAS28-CRP of 3.2 or less and no swollen joints. In the conventional group, the treatment goal was clinical remission. MAIN OUTCOMES AND MEASURES: Co-primary outcomes were proportions of patients achieving DAS28-CRP remission (DAS28-CRP <2.6) and with no radiographic progression (no increase in total van der Heijde-modified Sharp score) at 24 months. Significance testing for the primary outcome was based on 1-sided testing. Secondary outcomes were clinical and MRI measures of disease activity, physical function, and quality of life. RESULTS: Of 200 patients randomized (133 women [67%]; mean [SD] age, 61.6 [10.5] years; median baseline DAS28-CRP, 1.9 [interquartile range, 1.7-2.2]; van der Heijde-modified Sharp score, 18.0 [interquartile range, 7.0-42.5]), 76 patients (76%) in the MRI-guided group and 95 (95%) in the conventional group completed the study. Of these, 64 (85%) vs 83 (88%), respectively, reached the primary clinical end point (risk difference, -4.8% [1-sided 95% CI, -13.6% to + ∞; 1-sided P = .19]) and 49 (66%) vs 58 (62%), respectively, reached the primary radiographic end point (risk difference, 4.7% [1-sided 95% CI, -7.0% to + ∞; 1-sided P = .25). Of 10 key secondary end points, 8 were null and 2 showed statistically significant benefit for the MRI treat-to-target group. Seventeen patients (17%) in the MRI-guided treat-to-target group and 6 patients (6%) in the conventional treat-to-target group experienced serious adverse events. CONCLUSIONS AND RELEVANCE: Among patients with RA in clinical remission, an MRI-guided treat-to-target strategy compared with a conventional treat-to-target strategy did not result in improved disease activity remission rates or reduce radiographic progression. These findings do not support the use of an MRI-guided strategy for treating patients with RA. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01656278.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg B, et al. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial. JAMA. 2019. PMID: 30721294. doi:10.1001/jama.2018.21362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。